[Prognosis of patients with supranormal ejection fraction undergoing percutaneous aortic valve replacement]
- PMID: 40417342
- PMCID: PMC12097310
- DOI: 10.24875/RECIC.M24000465
[Prognosis of patients with supranormal ejection fraction undergoing percutaneous aortic valve replacement]
Abstract
Introduction and objectives: Several studies have shown that reduced (< 50%) left ventricular ejection fraction (LVEF) is an independent risk factor for cardiovascular events and mortality in patients with severe aortic stenosis (AS) undergoing valve replacement. Although patients with preserved LVEF (> 50%) have a better prognosis, there is a group with supranormal LVEF (≥ 70%) whose prognosis seems to differ due to their characteristics. The aim of this study was to evaluate outcomes after transcatheter aortic valve implantation (TAVI) in patients with severe AS and supranormal LVEF.
Methods: We performed a retrospective cohort study that included 1160 patients undergoing TAVI between 2007 and 2021 at Hospital Clínico San Carlos (Madrid, Spain). The patients were classified according to preoperative LVEF into reduced (< 50%), normal (50% to 69%), and supranormal (≥ 70%). Clinical, echocardiographic variables, and the following outcomes were compared: death from any cause at 30 days and at 1 year, death from cardiovascular causes at 1 year, and rehospitalization due to cardiovascular causes at 1 year.
Results: Of the 1160 patients with severe AS who underwent TAVI during the study period, 276 (23.8%) had reduced LVEF, 702 (60.5%) had normal LVEF, and 182 (15.7%) had supranormal LVEF. Patients with supranormal LVEF were predominantly men (82.9 ± 5.3 years) and had lower ventricular volumes, higher relative wall thickness, and concentric geometry. There were no differences in 30-day or 1-year mortality. However, rehospitalization for cardiovascular causes at 1 year was significantly higher in the supranormal LVEF group (LVEF < 50%: 29.2%; LVEF 50% to 69%: 27.4%; LVEF ≥ 70%: 34.4%; P < .043).
Conclusions: Patients with severe AS and supranormal preprocedural LVEF (≥ 70%) who underwent TAVI had a higher rate of cardiovascular rehospitalization at 1 year, with no differences in mortality.
Introducción y objetivos:: Se ha evidenciado en diversos estudios que la fracción de eyección del ventrículo izquierdo (FEVI) reducida (< 50%) es un factor de riesgo independiente de eventos y mortalidad en pacientes con estenosis aórtica (EA) grave tratados con recambio valvular. A pesar de que aquellos con FEVI conservada (> 50%) muestran mejor pronóstico, existe un grupo con FEVI supranormal (≥ 70%) que parece tener un pronóstico diferente por sus características particulares. El objetivo de este estudio fue evaluar los resultados del implante percutáneo de válvula aórtica (TAVI) en pacientes con EA grave y FEVI supranormal.
Métodos:: Estudio de cohorte retrospectiva que incluyó 1.160 pacientes tratados con TAVI en 2007-2021 en el Hospital Clínico San Carlos (Madrid, España). Se clasificaron según su FEVI preoperatoria en reducida (< 50%), normal (50-69%) y supranormal (≥ 70%). Se compararon variables clínicas y ecocardiográficas, y los siguientes desenlaces: mortalidad por cualquier causa a los 30 días y al año, muerte por causa cardiovascular al año y rehospitalización por causa cardiovascular al año.
Resultados:: De los 1.160 pacientes con EA grave que recibieron un TAVI durante el periodo del estudio, 276 (23,8%) se registraron con FEVI reducida, 702 (60,5%) con FEVI normal y 182 (15,7%) con FEVI supranormal. Los pacientes con FEVI supranormal eran predominantemente varones (82,9 ± 5,3 años), tenían menores volúmenes ventriculares, mayor grosor parietal relativo y geometría concéntrica. No hubo diferencias en la mortalidad a 30 días ni al año; sin embargo, la rehospitalización por causa cardiovascular al año fue significativamente superior en el grupo de FEVI supranormal (FEVI < 50%, 9,2%; FEVI 50-69%, 27,4%; FEVI ≥ 70%, 34,4%; p < 0,043).
Conclusiones:: Los pacientes con EA grave tratados con TAVI que presentaban FEVI supranormal (≥ 70%) preprocedimiento tuvieron una mayor tasa de rehospitalización por causa cardiovascular al año, sin diferencias en la mortalidad.
Keywords: Rehospitalization; Severe aortic stenosis; Supranormal ejection fraction; TAVI.
Copyright: © 2024 Sociedad Española de Cardiología.
Conflict of interest statement
CONFLICTO DE INTERESES: No hay conflicto de intereses.
Figures


Similar articles
-
Echocardiographic predictors of outcome in severe aortic stenosis patients with preserved or reduced ejection fraction.Clin Res Cardiol. 2024 Mar;113(3):481-495. doi: 10.1007/s00392-023-02350-w. Epub 2024 Jan 22. Clin Res Cardiol. 2024. PMID: 38252146 Free PMC article.
-
Incremental Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients with Preserved Ejection Fraction Undergoing Transcatheter Aortic Valve Implantation.J Am Soc Echocardiogr. 2022 Sep;35(9):947-955.e7. doi: 10.1016/j.echo.2022.04.013. Epub 2022 Apr 30. J Am Soc Echocardiogr. 2022. PMID: 35504527
-
Predictive Factors of Cardiac Function Recovery and Mortality in Patients with Reduced Ejection Fraction Undergoing Transcatheter Aortic Valve Implantation.Medicina (Kaunas). 2025 Feb 4;61(2):266. doi: 10.3390/medicina61020266. Medicina (Kaunas). 2025. PMID: 40005384 Free PMC article.
-
Left ventricular functional recovery and remodeling in low-flow low-gradient severe aortic stenosis after transcatheter aortic valve implantation.J Am Soc Echocardiogr. 2014 Aug;27(8):817-25. doi: 10.1016/j.echo.2014.04.021. Epub 2014 Jun 3. J Am Soc Echocardiogr. 2014. PMID: 24906801
-
Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation.Cardiovasc Revasc Med. 2022 Sep;42:55-61. doi: 10.1016/j.carrev.2022.02.023. Epub 2022 Feb 26. Cardiovasc Revasc Med. 2022. PMID: 35283064 Clinical Trial.
References
-
- 1. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly:disease prevalence and number of candidates for transcatheter aortic valve replacement:a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002-1012. - PubMed
- Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly:disease prevalence and number of candidates for transcatheter aortic valve replacement:a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002–1012. - PubMed
-
- 2. D'Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people:the OxVALVE Population Cohort Study. Eur Heart J. 2016;37:3515-3522. - PMC - PubMed
- D'Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people:the OxVALVE Population Cohort Study. Eur Heart J. 2016;37:3515–3522. - PMC - PubMed
-
- 4. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632. - PubMed
- Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632. - PubMed
-
- 5. Dahl JS, Eleid MF, Michelena HI, et al. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc Imaging. 2015;8:e002917. - PubMed
- Dahl JS, Eleid MF, Michelena HI, et al. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc Imaging. 2015;8:e002917. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials